Form 8-K Viking Therapeutics, For: Oct 23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
BTIG Reiterates Buy Rating on Viking Therapeutic (VKTX)
October 24, 2024 5:42 AM EDTBTIG analyst Justin Zelin reiterated a Buy rating and $125.00 price target on Viking Therapeutic (NASDAQ: VKTX).
The analyst comments "Viking reported 3Q24 earnings with focus on the higher dose oral VK2735 data expected at Obesity Week in a poster presentation... More
